Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies

Alzheimer's disease is one of the most devastating neurodegenerative diseases without effective therapies. Immunotherapy is a promising approach, but amyloid antibody structural information is limited. Here we simulate the recognition of monomeric, oligomeric, and fibril amyloid-β (Aβ) by three homologous antibodies (solanezumab, crenezumab, and their chimera, CreneFab). Solanezumab only binds the monomer, whereas crenezumab and CreneFab can recognize different oligomerization states; however, the structural basis for this observation is not understood. We successfully identified stable complexes of crenezumab with Aβ pentamer (oligomer model) and 16-mer (fibril model). It is noteworthy that solanezumab targets Aβ residues 16–26 preferentially in the monomeric state; conversely, crenezumab consistently targets residues 13–16 in different oligomeric states. Unlike the buried monomeric peptide in solanezumab's complementarity-determining region, crenezumab binds the oligomer's lateral and edge residues. Surprisingly, crenezumab's complementarity-determining region loops can effectively bind the Aβ fibril lateral surface around the same 13–16 region. The constant domain influences antigen recognition through entropy redistribution. Different constant domain residues in solanezumab/crenezumab/chimera influence the binding of Aβ aggregates. Collectively, we provide molecular insight into the recognition mechanisms facilitating antibody design.

[1]  Anne Corbett,et al.  Alzheimer's disease , 2011, The Lancet.

[2]  C. Dobson,et al.  Antibodies and protein misfolding: From structural research tools to therapeutic strategies. , 2014, Biochimica et biophysica acta.

[3]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[4]  R. Nussinov,et al.  Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains , 2017, Protein engineering, design & selection : PEDS.

[5]  Zaida Luthey-Schulten,et al.  NetworkView: 3D display and analysis of protein·RNA interaction networks , 2012, Bioinform..

[6]  Inbal Sela-Culang,et al.  The Structural Basis of Antibody-Antigen Recognition , 2013, Front. Immunol..

[7]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[8]  T. Comery,et al.  Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease , 2009, The Journal of Biological Chemistry.

[9]  Nicholas M. Glykos,et al.  Software news and updates carma: A molecular dynamics analysis program , 2006, J. Comput. Chem..

[10]  E. Ascari,et al.  Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segment , 2002 .

[11]  Ruth Nussinov,et al.  Selective molecular recognition in amyloid growth and transmission and cross-species barriers. , 2012, Journal of molecular biology.

[12]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[13]  L. Lopalco,et al.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti–HIV-1 human broadly neutralizing 2F5 antibody , 2012, Proceedings of the National Academy of Sciences.

[14]  R. Rich,et al.  Molecular basis for passive immunotherapy of Alzheimer's disease , 2007, Proceedings of the National Academy of Sciences.

[15]  A. Herrmann,et al.  Clearing the way for tau immunotherapy in Alzheimer's disease , 2015, Journal of neurochemistry.

[16]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..

[17]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[18]  A. Solomon,et al.  BENCE JONES PROTEINS AND LIGHT CHAINS OF IMMUNOGLOBULINS , 1969, The Journal of experimental medicine.

[19]  Malgorzata B. Tracka,et al.  Redistribution of Flexibility in Stabilizing Antibody Fragment Mutants Follows Le Châtelier’s Principle , 2014, PloS one.

[20]  D. A. Fernández‐Velasco,et al.  Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains , 2008, Proteins.

[21]  R. Nussinov,et al.  Multiple conformational selection and induced fit events take place in allosteric propagation. , 2014, Biophysical chemistry.

[22]  Janusz M. Bujnicki,et al.  PROTMAP2D: visualization, comparison and analysis of 2D maps of protein structure , 2007, Bioinform..

[23]  A. Dispenzieri,et al.  Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis , 2009, PloS one.

[24]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[25]  A. Bonvin,et al.  The HADDOCK web server for data-driven biomolecular docking , 2010, Nature Protocols.

[26]  Charles D. Schwieters,et al.  Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue , 2013, Cell.

[27]  A. Casadevall,et al.  Isothermal Titration Calorimetry Reveals Differential Binding Thermodynamics of Variable Region-identical Antibodies Differing in Constant Region for a Univalent Ligand* , 2008, Journal of Biological Chemistry.

[28]  J. Pons,et al.  Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. , 2012, Journal of molecular biology.

[29]  N. Toni,et al.  An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.

[30]  J A McCammon,et al.  Analysis of a 10-ns molecular dynamics simulation of mouse acetylcholinesterase. , 2001, Biophysical journal.

[31]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[32]  M. Buckle,et al.  Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies? , 1996, The Journal of clinical investigation.

[33]  Giulio Superti-Furga,et al.  Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation , 2001, Cell.

[34]  Mayuko Takeda-Shitaka,et al.  Interaction between the antigen and antibody is controlled by the constant domains: Normal mode dynamics of the HEL–HyHEL‐10 complex , 2003, Protein science : a publication of the Protein Society.

[35]  R. Wetzel,et al.  Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis. , 1996, Journal of molecular biology.

[36]  A. Solomon,et al.  Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia. , 1994, Clinical immunology and immunopathology.

[37]  R. Riek,et al.  3D structure of Alzheimer's amyloid-β(1–42) fibrils , 2005 .

[38]  G. Melacini,et al.  Human serum albumin inhibits Abeta fibrillization through a "monomer-competitor" mechanism. , 2009, Biophysical journal.

[39]  W. Weis,et al.  Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab , 2014, Alzheimer's Research & Therapy.

[40]  A. Solomon,et al.  Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). , 1982, The Journal of clinical investigation.

[41]  R. Tycko,et al.  Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. , 2006, Biochemistry.

[42]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[43]  R. Nussinov,et al.  Compilation and Analysis of Enzymes, Engineered Antibodies, and Nanoparticles Designed to Interfere with Amyloid‐β Aggregation , 2017 .

[44]  O. Schueler‐Furman,et al.  Improved side‐chain modeling for protein–protein docking , 2005, Protein science : a publication of the Protein Society.

[45]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[46]  G. Melacini,et al.  Stoichiometry and affinity of the human serum albumin-Alzheimer's Aβ peptide interactions. , 2011, Biophysical journal.

[47]  M. Ultsch,et al.  Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin , 2016, Scientific Reports.

[48]  D. Holtzman,et al.  Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy , 2004 .

[49]  David Baker,et al.  Protein-protein docking with backbone flexibility. , 2007, Journal of molecular biology.

[50]  G. Logroscino,et al.  Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? , 2014, Current opinion in psychiatry.

[51]  R. Nussinov,et al.  Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes. , 2016, Biochimica et biophysica acta.

[52]  Yanay Ofran,et al.  A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes , 2012, The Journal of Immunology.

[53]  M. Ultsch,et al.  Structure of Crenezumab Complex with A beta Shows Loss of beta-Hairpin. , 2016 .

[54]  G. Melacini,et al.  Aβ association inhibition by transferrin. , 2013, Biophysical journal.

[55]  A. Casadevall,et al.  The immunoglobulin constant region contributes to affinity and specificity. , 2008, Trends in immunology.

[56]  Jeffrey J. Gray,et al.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. , 2003, Journal of molecular biology.

[57]  N. Andreasen,et al.  Pathways to Alzheimer's disease , 2014, Journal of internal medicine.

[58]  R. Fonseca,et al.  Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). , 2003, Blood.

[59]  A. Casadevall,et al.  Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. , 2010, Molecular immunology.

[60]  R. Nussinov,et al.  Folding funnels and binding mechanisms. , 1999, Protein engineering.

[61]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[62]  R. Nussinov,et al.  Polymorphism in Alzheimer Aβ Amyloid Organization Reflects Conformational Selection in a Rugged Energy Landscape , 2010, Chemical reviews.

[63]  C. Masters,et al.  Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. , 2008, Journal of molecular biology.

[64]  H. Wolfson,et al.  Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .

[65]  Tong Li,et al.  Rigidity Emerges during Antibody Evolution in Three Distinct Antibody Systems: Evidence from QSFR Analysis of Fab Fragments , 2015, PLoS Comput. Biol..

[66]  M. Parker,et al.  Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies , 2015, Scientific Reports.

[67]  G. Melacini,et al.  In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin. , 2013, Journal of Alzheimer's disease : JAD.

[68]  J. Tainer,et al.  Unraveling the effect of changes in conformation and compactness at the antibody VL‐VH interface upon antigen binding , 1999, Journal of molecular recognition : JMR.

[69]  I. Mian,et al.  Structure, function and properties of antibody binding sites. , 1991, Journal of molecular biology.

[70]  Ozlem Keskin,et al.  Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies , 2007, BMC Structural Biology.

[71]  M. Schell,et al.  Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. , 1999, Biochemistry.

[72]  Brian D. Weitzner,et al.  Benchmarking and Analysis of Protein Docking Performance in Rosetta v3.2 , 2011, PloS one.

[73]  A. Mark,et al.  Fluctuation and cross-correlation analysis of protein motions observed in nanosecond molecular dynamics simulations. , 1995, Journal of molecular biology.

[74]  K. Sharp,et al.  On the relationship between NMR‐derived amide order parameters and protein backbone entropy changes , 2015, Proteins.

[75]  K. Olsen,et al.  Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: kappa IV immunoglobulin light chain. , 1998, Biochemical and biophysical research communications.

[76]  B. Volkman,et al.  Altered Dimer Interface Decreases Stability in an Amyloidogenic Protein* , 2008, Journal of Biological Chemistry.

[77]  M. Karplus,et al.  Collective motions in proteins: A covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations , 1991, Proteins.

[78]  K. V. van Acker,et al.  Effects of long-term treatment with anticonvulsant drugs. , 1973, The Journal of pediatrics.

[79]  G. Melacini,et al.  Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution. , 2013, Biophysical journal.

[80]  Charles L. Brooks,et al.  New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..

[81]  M. Oda,et al.  Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition. , 2008, Biochemistry.

[82]  Peter Güntert,et al.  Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril , 2016, Proceedings of the National Academy of Sciences.

[83]  Laxmikant V. Kale,et al.  NAMD2: Greater Scalability for Parallel Molecular Dynamics , 1999 .

[84]  H. Loetscher,et al.  Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.

[85]  Dan S. Tawfik,et al.  Antibody Multispecificity Mediated by Conformational Diversity , 2003, Science.

[86]  M. Parker,et al.  Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation , 2013, Scientific Reports.

[87]  Ruth Nussinov,et al.  Aβ(1–42) Fibril Structure Illuminates Self-recognition and Replication of Amyloid in Alzheimer’s , 2015, Nature Structural &Molecular Biology.

[88]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[89]  M. Manning,et al.  Thermodynamic Modulation of Light Chain Amyloid Fibril Formation* , 2000, The Journal of Biological Chemistry.